Skip to Content
Merck
  • Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus.

Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus.

Arthritis & rheumatology (Hoboken, N.J.) (2014-06-20)
Nele Gao, Julia Dresel, Volker Eckstein, Rimma Gellert, Hannah Störch, Ram K C Venigalla, Vedat Schwenger, Regina Max, Norbert Blank, Hanns-Martin Lorenz, Theresa Tretter
ABSTRACT

B cells with immunoregulatory properties (Breg cells) have been described in mice, but their role in the control of human immune responses is not well defined. We recently identified a human population of activated FSC(high) B cells that exhibited regulatory activity toward T helper cells. The aim of the present study was to test such induced Breg (iBreg) cells in patients with autoimmune disease. Purified CD19+FSC(high) B cells derived from patients with systemic lupus erythematosus (SLE) or from healthy donors, which were activated via their B cell receptor, were cocultured with CD3-stimulated CD4+ T helper cells from SLE patients or healthy donors. (3) H-thymidine incorporation, flow cytometry, and enzyme-linked immunosorbent assay (ELISA) were used to analyze proliferation, cytokine secretion, and surface marker expression. Although under costimulatory conditions, FSC(high) SLE B cells supported the proliferation of healthy donor T cells to a similar extent as donor B cells, their regulatory function was significantly diminished in B cell suppressor assays. Similar effects were seen when SLE T cells were used, confirming that SLE T cells were equally susceptible to iBreg cell signals as healthy donor T cells and that SLE iBreg cell defects were independent of T cell origin. B cell viability and expression of surface markers (CD25, CD80, and B7-H1) or cytokines (interleukin-6 [IL-6], tumor necrosis factor α, and IL-10) were comparable in the two B cell populations. There was no correlation between the extent of iBreg cell-induced inhibition and disease activity. CD19+FSC(high) B cells from patients with another systemic autoimmune disease, granulomatosis with polyangiitis (Wegener's) (GPA), exhibited no regulatory defects, which suggests that the iBreg cell defects were SLE-specific and not a general consequence of autoimmunity or inflammation. Induced Breg cells from SLE patients, but not GPA patients, are less effective in the control of T helper cell proliferation, which supports the reported skewed B cell repertoire in SLE. The malfunctioning SLE iBreg cells might allow the overstimulation of immune responses and contribute to the initiation and/or perpetuation of disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fluorescein isothiocyanate isomer I, suitable for protein labeling, ≥90% (HPLC), powder
Sigma-Aldrich
Fluorescein isothiocyanate isomer I, ≥97.5% (HPLC)
Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in E. coli, ~10000 U/mL
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in Pichia pastoris, suitable for cell culture
Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in HEK 293 cells, suitable for cell culture, endotoxin tested
Sigma-Aldrich
Interleukin-2, human, Animal-component free, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, ≥90% (HPLC)